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Key points:  
- AIH is a rare disease, which is the result of an autoimmune destruction of the hepatocytes, 
manifesting with high liver aminotranferases and serum autoantibodies that may be specific for the 
disease.  
- PBC and PSC are chronic autoimmune cholestatic diseases that affect the biliary tree. PBC is 
characterized by AMA positivity in almost all cases, while conversely, PSC has no association with 
autoantibodies, suggesting a different pathogenesis. 
- Rheumatic diseases are found in nearly 20% of patients suffering from autoimmune liver diseases, 
and may be associated with different prognoses for the patients. For this reason, the identification of 
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the co-occurrent disease at an early stage or even pre-clinically (using autoantibodies) is of pivotal 
importance.  
- Bone density is reduced in patients with AIH due to prolonged steroid use and in PBC / PSC due 
to chronic cholestasis; therefore, osteoporosis management is an important issue in the care of these 
patients. 
- Treatment options should be personalized to address coexisting conditions, especially if 
overlapping with specific rheumatic or autoimmune diseases.  
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Abstract. 
Autoimmune liver diseases coexist with rheumatic disorders in approximately 30% of cases and 
may also share pathogenetic mechanisms. Autoimmune liver diseases result from an immune-
mediated injury of different tissues, with autoimmune hepatitis (AIH) targeting hepatocytes, 
primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) targeting 
cholangiocytes. Sjögren’s syndrome is diagnosed in 7% of AIH cases and serological autoimmunity 
profiles are a common laboratory abnormality, particularly in the case of serum anti-mitochondrial 
(PBC) or anti-liver kidney microsomal antibodies (AIH). Therapeutic strategies may overlap 
between rheumatic and autoimmune liver diseases and practitioners should be vigilant in managing 
bone loss. 
 
  
 4 
Introduction. 
The link between autoimmune liver diseases and rheumatologic disease traces back to the first 
report in the mid-1950s, when findings of active chronic hepatic disease were described in the 
setting of systemic lupus erythematosous (SLE).  This led to the concept of “lupoid hepatitis” with 
positive LE cell tests and mild signs of rheumatic disease 1,2. When discussing autoimmune liver 
disease, it is possible to distinguish autoimmune hepatitis (AIH, affecting hepatocytes) from 
primary biliary cholangitis (PBC, until recently known as primary biliary cirrhosis), and primary 
sclerosing cholangitis (PSC) based on the target tissue3,4. Cirrhosis and liver failure are potential 
complication shared by inflammatory hepatobiliary diseases, regardless of the target tissue, while 
the pathogenesis and therapeutics may vary within the clinical spectrum 5. The epidemiology of 
autoimmune liver diseases is similar to other rare autoimmune or inflammatory disorders.6-8 
Similarly, serum autoantibodies represent the hallmark for AIH and PBC, but not PSC, and are 
usually positive years before the diagnosis (Table 1) 9-11.  
Since the earliest reports, several others have shown the associations between PBC and systemic 
sclerosis (SSc), 12,13 as well as Sjögren’s syndrome (SjS) 14. Moreover, the epidemiologic links 
between these liver diseases and systemic rheumatic manifestations, are also reflected in shared 
pathogenetic mechanisms.  This is elegantly represented by the concept of “autoimmune 
epithelitis,” coined as a descriptor for PBC and SjS 15. Serological profiles are also similar with 
regard to antinuclear antibodies (ANA) positivity 16 and common laboratory abnormalities are 
present, as is the case for hypergammaglobulinemia 17. Most importantly, therapeutic strategies may 
also overlap, since steroids represent the first-line therapy in most cases 18, while new targeted 
approaches are emerging 19,20. Non-classical associations have been also reported between 
spondyloarthritis and PSC, with regard to inflammatory bowel diseases (IBD) 21. Finally, since 
corticosteroids and chronic liver diseases are associated with bone density loss, osteoporosis and 
bone fractures are conditions demanding the attention of the rheumatologist managing such patients 
22-24. 
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The aims of the present review are 1) to provide an overview of the characteristics of the three 
major autoimmune liver diseases, namely AIH, PBS and PSC; 2) elucidate the existing associations 
between these conditions and rheumatic diseases.  Particular attention is paid to both the shared and 
unique epidemiology, serum autoantibodies, and treatments, as well as the approach to bone density 
loss.  
 
Autoimmune hepatitis. 
AIH is a chronic inflammatory disease of unknown etiology resulting from the immune-mediated 
destruction of hepatocytes with autoimmune features 25,26. AIH is characterized by the presence of 
typical but non-specific findings on liver biopsy, serum autoantibodies, and elevated serum 
aminotransferases and gamma-globulins 27. The incidence, though not precise, , is estimated at 
approximately 1 per 100,000 person-years, with higher possible incidence in Scandinavia 28. AIH 
most commonly affects women, with a male:female ratio of 1:4 28, and manifests a two-peak 
incidence during adolescence and at 30–45 years of age 25,29. The onset of AIH is most frequently 
insidious, with 20–30% of patients presenting with an acute icteric hepatitis, consistently associated 
with hypergammablubulinemia. Clinical manifestations are non-specific and include 
hepatosplenomegaly, jaundice, anorexia and fatigue 27,30. The most common extrahepatic 
manifestations are arthralgia and rash. 
Clinical features 
Two types of AIH are distinguished, primarily based on autoantibody patterns; i.e. AIH type 1 with 
ANA and/or anti-smooth muscle antibodies (anti-SMA), and AIH type 2 with anti-liver kidney 
microsomal type 1 antibody (anti-LKM1) and/or anti-liver cytosol type 1 antibody (anti-LC1). Type 
I AIH (AIH-1) can affect individuals of any age and sex. Patients with HLA DRB1*0301 AIH-1 are 
more likely to be male, present with high IgG levels, be ANA/anti-SMA positive, deteriorate 
despite glucocorticoid treatment, and progress more frequently to liver transplantation. Type II AIH 
(AIH-2), primarily affects girls and young women, and has been linked to alleles encoding the DR3 
 6 
(DRB1*0301) and DR7 (DRB1*0701) molecules 26.  It also associates with anti-LKM antibodies 
27,31,32. The diagnosis of AIH is defined as definite or probable, based on the Diagnostic Criteria of 
the International Autoimmune Hepatitis Group (IAIH-G, Table 2) 33,34. The clinical criteria for the 
diagnosis are sufficient to establish or rule out a definite or probable AIH in the majority of 
patients. The revised scoring system was developed as a research tool to ensure the comparability of 
study populations in clinical trials, and can be used to assess treatment response (Table 3), similar 
to classification criteria utilized in rheumatology 34. A pretreatment score of 10 points or higher, or 
a posttreatment score of 12 points or higher, indicate ‘‘probable’’ AIH at presentation, with a 
sensitivity of 100%, a specificity of 73%, and diagnostic accuracy of 67%. A pretreatment score of 
15 points, indicative of ‘‘definite AIH’’ has a sensitivity of 95%, a specificity of 97%, and a 
diagnostic accuracy of 94% 35.  
The clinical course of untreated AIH results in significant mortality, with 5- and 10-year survival 
rates of 50% and 10% respectively.  The use of glucocorticoids has dramatically improved the 
disease course with a 10-year survival rate now exceeding 90% 25. The complications associated 
with AIH are similar to those of other progressive liver diseases, as chronic hepatitis can evolve to 
cirrhosis and ultimately to hepatocellular carcinoma (HCC), despite the use of immunosuppressives. 
At the time of diagnosis, approximately 30% of adults have histological evidence of cirrhosis; when 
appropriately treated, however, only a small number develop cirrhosis during follow-up if 
biochemical and histology inflammation resolves. The occurrence of HCC in patients with AIH is 
rare and only develops in long-standing cirrhosis. In the absence of definitive data, primary liver 
neoplasia incidence is assumed to be similar to other non-viral cases of cirrhosis 25.  
Association with rheumatic diseases 
AIH was originally described in association with SLE and currently extrahepatic autoimmune 
manifestations are found in 20-50% of patients 36, with the most common being autoimmune 
thyroiditis, diabetes, rheumatoid arthritis (RA) and ulcerative colitis (UC). Up to 43% of AIH cases 
will have a family history of autoimmune diseases, in particular thyroid diseases and type 1 diabetes 
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37. The occurrence of other autoimmune diseases in AIH is included in the original and revised 
International Autoimmune Hepatitis Scoring System (Table 3) 33. Concurrent autoimmune 
disorders tend to cluster in women with AIH type 1, particularly if positive for the human leukocyte 
antigen (HLA)-DR4 38. Moreover, elderly patients with AIH have higher frequency of concurrent 
rheumatic conditions than young adults 39. SjS has been reported in up to 7% of AIH patients, while 
RA in 2-4%. Though liver dysfunction has been reported in up to 60% of SLE patients, the 
overlapping with AIH is rare 36. 
An AIH-like entity linked to anti-TNF treatment has recently been described in case reports.40 
Though these result in a significant liver injury, the pathogenesis remains clear 41. Liver biopsy 
appears useful, however the differentiation between drug-induced liver injury is not an easy task. 
Interestingly, most cases respond well to corticosteroids 42.  
Autoantibodies 
Autoantibodies represent a critical feature of AIH and may guide the diagnosis (Table 2). In 2004, 
the  IAIH-G established procedures and reference guidelines for more reliable serum autoantibody 
testing to overcome the lack of standardization 43. In addition to serum ANA, anti-SM, and anti-
LKM, 44 other autoantibodies should also be sought in suspected cases, including anti-LC1, 
perinuclear anti-neutrophil cytoplasmic antibodies (pANCA), SLA/LP, and the anti 
asialoglycoprotein receptor antibodies 45. Finally, less specific autoantibodies may be detected in a 
subset of patients, including anticardiolipin, anti-chromatin, anti-dsDNA, rheumatoid factor (RF), 
anti-histones, anti-Ro/SSA, and anti-cyclic citrullinated peptides (anti-CCP) antibodies. Serum 
ANA were the first autoantibodies observed in AIH sera over 50 years ago and remain the most 
sensitive marker of AIH 46. These most frequently produce a homogeneous or speckled pattern. 
However, the test is not specific for AIH, since ANA positivity is not uncommon in viral diseases, 
other autoimmune liver diseases, as well as in up to 15% of healthy subjects, especially in older age 
groups 47. Serum SMA are autoantibodies reacting with different proteins (actin, tubulin, vimentin, 
desmin, cytokeratins) of the cytoskeletal components (microfilaments, microtubuli, intermediate 
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filaments). Their presence characterizes both autoimmune (AIH-1, coeliac disease) and viral 
diseases (chronic hepatitis C, infectious mononucleosis). When detected at high titers (>1:80), they 
are considered a sensitive marker for AIH-1, being found in up to 80% of cases. A recent study 
showed that anti- SMA-T/G positive subject with normal liver function are at low risk of 
progression to AIH, while positive SMA and raised ALT (>55IU/L) are at higher risk, though the 
positive predictive value is only 22% 48. Serum autoantibodies against LKM-1 are the main 
serological markers of AIH-2, recognizing the proximal renal tubule and hepatocellular cytoplasm. 
Serum anti-SLA/LP antibodies are occasionally found in AIH patients who are negative for ANA, 
SMA, or anti-LKM and are cumulatively detected in 10–30% of cases of AIH-1 and -2. Anti-
SLA/LP antibodies are detectable by radioimmunoassay and enzyme-linked immunosorbent assay 
(ELISA) but not by immunofluorescence and are directed against different epitopes of a UGA 
tRNA suppressor. Anti-LC1 antibodies are detected by indirect immunofluorescence in sera from 
up to 50% of patients with type 2 AIH and less frequently in type 1 AIH or chronic hepatitis C. 
Importantly, however, anti-LC1 are the only detectable markers in 10% of AIH cases. Interestingly, 
serum anti-LC1 antibodies correlate with AIH severity and progression. Antibodies to the 
asialoglycoprotein receptor are observed in up to 90% of patients with AIH and often coexist with 
other autoantibodies, though they lack specificity for the disease. Similar to anti-LC1, however, 
anti-asialoglycoprotein titers are associated with a more florid inflammatory disease activity and 
may allow monitoring of treatment response.  
With regard to non-specific antibodies, anti-CCP can be found in 9% of AIH sera, and their 
detection is independent of concurrent RA but may distinguish early stage RA from nonspecific 
arthralgia 39. Moreover, it has been reported than anti-CCP positive subjects are at higher risk of 
cirrhosis at diagnosis and die more frequently from hepatic failure 21. Anti-cardiolipin antibodies 
occur in nearly 40% of AIH, which is more frequently than hepatitis C (20%) and B (14%) 
infections. The presence of anti-cardiolipin IgG/IgM is associated with cirrhosis and inflammatory 
activity 49, with the IgM subtype being more frequent in AIH than PBC 50. Further, pANCA can be 
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detected by indirect immunofluorescence in sera from patients with AIH-1, but also in a subgroup 
of patients with PSC or chronic viral hepatitis. Antibodies to histones are present in 35% of ANA-
positive patients with autoimmune hepatitis, while anti-dsDNA are detected in 23–34% cases, 
depending on the nature of the assay and substrate used for their detection 51. Patients with anti-
histones are not distinguished by the severity of their disease 52, while anti-dsDNA positive subjects 
do not respond or respond less to corticosteroid treatment 53.  
Therapy 
In contrast to PBC and PSC, immunosuppressants represent the treatment of choice for AIH, based 
on the good bio-chemical and histologic response, and survival (Table 4) 43,54. Glucocorticoids--in 
particular prednisone--in monotherapy or in combination with azathioprine are the first-line 
treatment.  These induce remission (i.e. normal ALT and IgG) in over 80% of the patients, 
regardless of the presence of cirrhosis 31. Once achieved, remission can be maintained with 
azathioprine alone after steroid tapering. The dosage of azathioprine is typically low compared to 
rheumatic diseases, usually requiring only 50 mg/day and never exceeding 150 mg/day 18. Relapses 
following steroid discontinuation are common, since only 20% of patients remain in sustained 
remission. It should be noted, however, that subgroups of patients manifest disease progression 
(approximately 10%) or are intolerant to standard therapy (13%). In such patients, other drugs have 
been anecdotally tried, including methotrexate 55, cyclophosphamide, tacrolimus, ursodeoxycholic 
acid, cyclosporine and mycophenolate mofetil, the latter two constituting the most frequently 
reported alternatives 18,56. Biologic therapies commonly used in rheumatology are of particular 
interest, as pro-inflammatory cytokines, i.e. tumor necrosis factor (TNF)-alpha, are involved in AIH 
pathogenesis 18. Infliximab has been used in refractory cases of AIH with reduction of 
aminotransferases and IgG levels 57. Rituximab has been tried in a few refractory AIH cases, 
resulting in improved liver enzymes and IgG, no significant side effects, and a reduction in 
prednisolone dose for some patients 58. Future developments may include regulatory T cell therapy, 
which could allow the avoidance of prolonged often life-long global immunosuppression in patients 
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with AIH 59. Liver transplantation is the most definitive treatment for AIH patients presenting with 
acute liver failure or end-stage chronic liver disease and for those with HCC that meet the transplant 
criteria. Although liver transplantation for these patients is very successful, AIH may recur after 
transplant. AIH patients undergoing liver transplant have overall 5- and 10-year survival rates of 
90% and 75%, respectively, although infectious complications and disease recurrence are common 
60-63.   
 
Primary biliary cholangitis 
PBC is a chronic cholestatic disease characterized by high-titer serum anti-mitochondrial antibodies 
(AMA) in nearly 100% of patients when sensitive techniques are used.64 It results in autoimmune-
mediated destruction of the small and medium-sized intrahepatic bile ducts 17,65. PBC prevalence 
varies substantially according to geography; the highest rates appear in the northern US with a point 
prevalence of 402 per million in Minnesota 66. Similar to other autoimmune diseases, PBC most 
commonly affects women, with a 1:9 male:female ratio 17, and the average age at PBC diagnosis is 
within the 5th and 6th decades of life 17. 
Recently, PBC nomenclature has shifted from the term “cirrhosis” to “cholangitis”, which is more 
precise and removes the stigma associated with cirrhosis. This change reflects the dramatically 
improved PBC prognosis and treatment, since nowadays, two out of three patients diagnosed with 
PBC and treated with ursodeoxycholic acid (UDCA) have an expected survival comparable to the 
general population and only a minority will ever develop cirrhosis 67,68.  
Clinical features 
Early PBC symptoms are classically described as fatigue and pruritus while physical findings may 
include skin hyperpigmentation, hepatosplenomegaly, and (rarely) xanthelasmas. Fatigue and 
pruritus are nonspecific symptoms present in 70% of PBC patients. Conversely, end-stage 
symptoms are secondary to the complications of liver cirrhosis, including ascites, jaundice, hepatic 
encephalopathy, and upper digestive bleeding. Portal hypertension is frequently found in patients 
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with PBC and, importantly, does not imply the presence of liver cirrhosis. Metabolic bone disease is 
elevated in PBC compared to sex- and age-matched healthy individuals (see below). Similar to 
other types of cirrhosis, end-stage PBC can be complicated by the occurrence of HCC. The 
progression of PBC varies widely, and the factors influencing the severity and progression of the 
disease are largely unknown. The presence of symptoms at presentation, however, are a major 
factor determining PBC survival rates; asymptomatic PBC produces 10-year survival rates shorter 
than the general population, but symptomatic PBC produces even shorter survival rates 68. 
The diagnosis of PBC is generally based on the presence of two of the following three criteria: (1) 
biochemical evidence of cholestasis with elevation of alkaline phosphatase activity over six months; 
(2) presence of serum AMA at significant titers; and (3) histological non-suppurative cholangitis 
and destruction of small or medium-sized bile ducts on biopsy specimen. The differential diagnosis 
includes a cholestatic drug reaction, biliary obstruction, sarcoidosis, AIH and PSC (Table 4) 69.  
Association with rheumatic diseases 
PBC is commonly associated with a number of extrahepatic autoimmune conditions. A recent 
monocentric study identified a co-occurrence in more than 60% of patients, with the most common 
being SjS in 30% of patients, followed by Raynaud’s phenomenon in 18%, and Hashimoto’s 
thyroiditis. PBC and SSc are associated in 6% of cases 70, while a higher frequency of RA (up to 
10%) has been reported since the 1970s 71,72. PBC has also been reported in the presence of HLA-
B27 enthesopathy.73  Interestingly, 5% of PBC cases also suffer from autoimmune cutaneous 
conditions 74, 75. Surprisingly, when extrahepatic autoimmune diseases co-occur with PBC, the 
cases tend to be less severe; severe SjS occurs in 10.5% of PBC cases, and the PBC disease is 
usually milder and at early stage (stage I-II at liver histology) in the presence of SjS 76,77. The same 
observation has been made with PBC and SSc. PBC most commonly associates with limited 
cutaneous SSc (lSSc), and patients with PBC/SSc overlap have a slower rate of liver-disease 
progression compared to matched patients with PBC alone 78. Female sex is the only significant risk 
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factor for at having a second autoimmune condition 70, while neither autoantibodies nor liver 
histology differ.  
Autoantibodies 
PBC is characterized serologically by the presence of AMA, which are highly specific for the 
disease.  These antibodies are found in 90-95% of PBC patients compared with less than 1% of 
healthy subjects 79. Similar to other autoimmune diseases, AMA positivity arises years before the 
development of PBC 9, and AMA are included in the internationally-accepted criteria for PBC 
diagnosis (Table 5) 80. AMA are directed against components of the 2-oxoacid dehydrogenase (2-
OADC) family of enzymes within the mitochondrial respiratory chain, most frequently the E2 and 
E3-binding protein (E3BP) components of the pyruvate dehydrogenase complex and the E2 
components of the 2-oxo glutarate dehydrogenase and branched-chain 2-oxo acid dehydrogenase 
complexes 81. All three antigen epitopes contain the motif DKA, with lipoic acid covalently bound 
to the lysine (K) residue 78. ANA have been identified in 52% of patients, with the most specific 
patterns being “nuclear-rim” and “multiple nuclear dots”, produced by antibodies directed against 
the nuclear membrane gp120 and nucleoporin 62, and the nuclear body sp100, sp140 and 
promyeolocytic leukaemia proteins, respectively (Table 1) 82-85. ANA-positive patients are more 
frequently AMA-negative, possibly because of the lack of a masking effect of these latter antibodies 
in such sera. While ACA are most specific for lSSc, found in up to 90% of cases, they are also 
detectable in 9-30% of PBC patients. This prevalence exceeds that of the PBC/SSc overlap 
syndrome 86,87. ACA recognize six centromere polypeptides belonging to the kinetochore proteins: 
CENP-A, CENP-B, CENP-C, CENP-D, CENP-E, CENP-F, with the major autoantigen being 
CENP-B. The clinical significance of ACA in PBC remains ill-defined as it is unclear whether 
ACA represents a pre-clinical marker of lSSc or a subclinical form of the disease. Moreover, ACA 
could simply represent an epiphenomenon of the immune dysregulation present in PBC 78. Some 
have posited that since ACA can predict the development of SSc and since early SSc may be 
frequent in PBC, these may facilitate timely detection of complications, preventing disability and 
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reducing the probability of liver transplantation 88,78. In any case, patients with PBC and positive 
ACA with SSc-related symptoms should be assessed for organ involvement, and in particular, 
assessment of pulmonary arterial hypertension by echocardiography should be considered in all 
PBC/SSc patients. Unfortunately, currently utilized tools to predict this pulmonary arterial 
hypertension (e.g. the DETECT score) have not been evaluated in PBC patients 89. Furthermore, 
while PBC/SSc seems to have a milder disease course, ACA positive PBC patients have a more 
severe bile duct injury and more frequently portal hypertension 78. With regard to other 
autoantibodies 90, anti-ENA are positive in up to 40% of PBC cases, regardless of the extrahepatic 
autoimmunity 70, with no effect on disease severity or progression. Anti-Ro/SSA are found in 
PBC/SjS overlap in 10% of cases 90, anti-dsDNA in 22% of PBC patients 90 while anti-cardiolipin 
IgM positive in 75% of PBC, advanced stage disease 91.  
Therapy 
PBC treatment is currently based on UDCA, which is the only approved drug. Its mechanism of 
action is incompletely understood and possibly dependent on the various phases of the disease 5,92. 
During the early disease, short-term glucocorticoids might be effective, however, prolonged use 
raises safety concerns. Budesonide, due to its high first-pass metabolism, has minimum systemic 
adverse effects, and, at 6–9 mg daily, has been demonstrated to be superior to UDCA both in terms 
of histology and biochemical markers. Other immunosuppressants, such as methotrexate and 
azathioprine, have also been suggested and there is evidence supporting the use of the latter in PBC 
with autoimmune hepatitis overlap syndrome 93. The use of biologics targeting TNF-alpha has been 
reported in few cases of overlap syndromes with rheumatic diseases 94,95. In the last years, improved 
understanding of PBC pathogenesis has led to the testing of new targeted therapies, especially those 
modulating the IL-17/23 axis. Ustekinumab, a monoclonal antibody against the p40 subunit, 
however, demonstrated only a very modest decrease in ALP after 28 weeks of therapy, and was 
otherwise deemed ineffective19. Other therapies targeting T cells 96, including those that bind 
CTLA-4 (abatacept) or antagonize CD40 (FFP104) are under investigation 69,97,98. Of note, the use 
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CTLA-4 Ig in PBC murine model prevents cholangitis manifestations (AMA production, 
intrahepatic T-cell infiltrates, and bile duct damage) and reduces disease severity in established 
murine disease 99. When the disease has already progressed and bile is accumulated, obeticholic 
acid (OCA)--an analogue of chenodeoxycholic acid with a much higher affinity to the farnesoid X 
receptor (FXR)--has been shown to decrease bile synthesis, promote secretion, and induce liver 
regeneration in animal models. Furthermore, a recent Phase III trial of OCA administered with 
UDCA or as monotherapy for 12 months demonstrated decreases in alkaline phosphatase and total 
bilirubin levels compared with placebo 97. Ultimately, UDCA represents the cornerstone therapy of 
PBC and dosages ranging from 13 to 15 mg/kg lead to optimum bile enrichment, with 50% of 
patients normalizing their alkaline phosphatase. Other immunosuppressive treatments should be 
started only in combination with UDCA.  
Liver transplantation may be necessary for end-stage PBC, with survival rates of 92% and 85% at 1 
and 5 years after transplant, respectively. Recurrence is common seems to be influenced by 
immunosuppressives, while the use of UDCA for recurrence is safe and recommended. 
 
 
Primary sclerosing cholangitis 
PSC is a progressive cholestatic liver disease of unknown etiology presenting with chronic 
inflammatory features of the bile ducts of any size and associated with significant morbidity and 
mortality 100,101. In contrast to PBC, PSC can affect all tracts of the biliary tree, including the 
extrahepatic bile ducts visible with imaging modalities and the small bile ducts observed via liver 
histology. The prevalence of PSC is approximately 10/100000 in Northern Europe 28 and in the US, 
while it is far less common in Southern Europe and Asia; recent data from the Olmstead County, 
Minnesota, report a prevalence of 20.9 per 100 000 men and 6.3 per 100 000 women 102. Different 
from PBC and AIH, PSC affects more frequently men, with a 2:1 male:female ratio 102.  
Clinical features 
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PSC symptoms are generally nonspecific and include abdominal pain, jaundice, and fever in the 
case of bacterial cholangitis, while at more advanced stages, symptoms include those typical of 
decompensated cirrhosis or neoplasia. Commonly, PSC is complicated by episodic bacterial 
cholangitis precipitated by biliary strictures. Discrete subgroups of patients manifest the “small-
duct” or overlap syndrome variants. Due to the nonspecific symptoms, PSC is usually diagnosed 
during routine blood tests in otherwise healthy individuals or patients with IBD 103. Testing 
characteristically reveals a biochemical cholestatic pattern, as represented by elevated serum 
alkaline phosphatase and γ-glutamyltransferase, though tests of liver function are normal until late 
stages. Imaging (particularly bile duct MRI or endoscopy) represents a useful diagnostic tool, as it 
may identify the classic strictured and dilated intrahepatic or extrahepatic bile ducts 102. Performing 
a liver biopsy is generally not necessary for the diagnosis of PSC, except in the case of small-duct 
PSC which requires histologic examination.  The natural history of this form is relatively benign 
and only a minority (12%) of patients progress to classical PSC. The median timespan from 
diagnosis to liver-related death or liver transplantation is 18 years, and the prognosis is influenced 
by the onset of cholangiocarcinoma (CCA).  CCA is more common with chronic biliary 
inflammation and difficult to distinguish from stricturing PSC 101.  
Association with rheumatic diseases 
The association of PSC with IBD is well established. Nearly 70% of PSC cases also demonstrate 
findings of IBD 104, frequently in mild asymptomatic forms, while 7% of IBD patients have PSC 
105. Liver abnormalities are more frequently found in psoriatic patients, and this is typically 
attributed to non-alcoholic or alcoholic fatty liver 106. However, in generalized pustular psoriasis, a 
less common form of psoriasis associated with extra-cutaneous manifestations, evidence for biliary 
involvement has been suggested, and neutrophilic cholangitis has been observed on liver biopsy, 
while magnetic resonance cholangiopancreatography showed features similar to those observed in 
PSC 107.  
Autoantibodies 
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In contrast to other autoimmune liver diseases, autoantibodies are of limited use in the diagnosis of 
PSC due to low sensitivity and specificity; only a limited percentage of patients (33%) have positive 
p-ANCA 108,109, for example. Only for PSC forms overlapping with AIH is serum ANA typically 
detected. 
Therapy 
The treatment of PSC is largely an unmet need and currently includes medical and endoscopic 
measures, short of liver transplantation 110,111. UDCA has been investigated in several clinical trials, 
with conflicting results. Overall, the available evidence suggests that UDCA does not produce a 
substantial change in the course of PSC, despite remaining the most prescribed drug. However, it 
appears that high-dose UDCA (20 mg/kg/day) or norUDCA, a side chain-shortened homologue of 
UDCA, may reduce reduced biochemical indices of cholestasis 112, the rate of progression, and 
might prevent the development of colon cancer (particularly in patients with UC/PSC overlap). 
Based on these inconclusive data, the use of UCDA in PSC varies widely, reflecting regional 
practice trends rather than science. Endoscopic interventions are indicated to treat complicated PSC 
through the dilation of short- and long-segment stenosis of the common bile duct and short-segment 
stenosis of the hepatic ducts near to the bifurcation. The treatment can be repeated over time once 
restenosis ensues and resulting survival rates are higher compared to patients not treated 
endoscopically. Biologics, mainly anti-TNF, have been used in PSC with concomitant IBD or 
rheumatic diseases with improvement in laboratory measurements 113,114 but patients with PSC are 
generally excluded from IBD clinical trials, thus preventing firm conclusions regarding efficacy. 
Finally, PSC represents an important indication for liver transplantation since patients are younger 
than their counterparts with PBC. Recurrence of disease occurs in 20–40% of transplanted patients 
during prolonged follow-up. The ability of UDCA to prolong survival after disease recurrence 
remains a point on contention. 
 
Overlap syndromes. 
Commentato [L1]: Consider cutting...out of place in the 
treatment section. 
Commentato [CS2]: I would maintain this as it is a less 
known secret for PSC people 
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Autoimmune liver diseases, similarly to rheumatic disease, may overlap and present with both 
hepatocellular and cholangiocellular patterns according to biochemical, histologic, and imaging-
based analysis. When left without treatment, these patients show a more progressive course toward 
liver cirrhosis and failure. AIH–PBC overlap syndrome is found in 10% of adults with AIH whereas 
AIH–PSC overlap syndromes affects 6–8% of children, adolescents, and young adults with AIH; 
PBC-PSC overlap syndrome is exceptionally rare (Table 6). Besides overlaps, transitions are also 
possible in rare cases from PBC to AIH, AIH to PBC, or AIH to PSC 115.  
AIH may have an atypical presentation with serum alkaline phosphatase elevation, AMA positivity, 
histologic features of bile duct injury/loss, or cholangiographic findings of focal biliary strictures 
and dilations. These manifestations characterize the overlap syndromes. The clues to an overlap 
syndrome consist of: (1) serum alkaline phosphatase >2-fold upper normal limit (ULN) at 
presentation, which is present in only 20% of AIH patients; (2) serum GGT >ULN unimproved or 
worsened during therapy; (3) AMA positivity; (4) histologic findings of bile duct injury or loss; (5) 
concurrent IBD; (6) corticosteroid treatment failure or incomplete response 115.  
Overlap features of PBC usually refers to simultaneous AIH in patients who have a diagnosis of 
AMA-positive PBC and not to patients with AIH who have coincidental AMA. AMA occur in 
about 5% of AIH patients in the absence of other biliary features (‘‘serological overlap’’), but may 
disappear or persist for decades without an evolution into PBC. Approximately 4% of PBC cases 
have simultaneous features of AIH. There are two different scoring systems that have been used to 
evaluate patients with PBC for simultaneous evidence of overlapping AIH: (1) the IAIH-G score; 
(2) looking for the presence of two of the three following features: (i) ALT activity 5 times upper 
limits of normal; (ii) IgG 2 times upper limits of normal and/or positive anti–SMA antibody; and 
overlap by (iii) liver biopsy with moderate or severe periportal or periseptal inflammation. A 
PBC/AIH overlap syndrome may also refer to patients with sequential PBC followed by AIH, a 
condition occurring in 2.4% of cases. In these cases, the diagnosis of PBC with positive AMA 
occurs first and initially responds biochemically to UDCA therapy; subsequently, these patients 
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present with clinical features of AIH, lose their AMA seropositivity, exhibit liver histology more 
typical of AIH, and respond to immunosuppressive therapy.  
The term ‘autoimmune cholangitis’ was first coined to indicate AMA-negative PBC, possibly with 
serum ANA. More recently, a broader concept has emerged that includes: (1) serum ANA and/or 
SMA positivity and/or hyper-gammaglobulinemia; (2) serum AMA negativity by 
immunofluorescence; (3) biochemical and/or histological features of cholestatic and hepatocellular 
injury; and (4) exclusion of chronic viral, metabolic, or toxic liver disease. This definition possibly 
subsumes PBC with atypical presentation, small-duct PSC, idiopathic adulthood ductopenia, AIH 
with bile duct damage, concurrent AIH and small-duct PSC, and various transitional stages of the 
classic diseases. Consensus is still wanting on this issue, and standardization of diagnostic criteria 
for overlap syndromes is impeded by their uncommon occurrence in the setting of rare diseases.  
 
Osteometabolic consequences of chronic autoimmune liver disease. 
Advancements in the management of autoimmune liver diseases and cirrhosis complications have 
increased survival rates. However, longer survival rates, compounded by an aging population, have 
increased the risk of complications such as osteoporosis.  Osteoporosis is associated with increased 
risk of fracture, which is two-fold higher in cirrhotic patients regardless of the liver disease 
etiology, and persists for years after liver transplantation 116-119. Moreover, patients receiving 
glucocorticoids for AIH suffer an additional decrease in their bone mass.  
According to the WHO definition, osteoporosis is diagnosed when bone density is less than 2.5 
standard deviations below the peak value obtained from normal adults and adjusted for gender (T 
score) 120. This definition is limited insofar as the threshold was established from studies of 
postmenopausal Caucasian women, rather than for patients with liver diseases.117 Therefore, some 
authors favor the term hepatic osteodystrophy, though this term also includes osteomalacia 121. 
The mechanisms of cirrhosis-related osteoporosis are not fully understood, but it is generally 
recognized that the association between liver and bone diseases occurs due to an imbalance of bone 
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turnover, which depends on the osteoblastic and osteoclastic activity 122. In PBC, while the exact 
mechanism is also not completely understood, there is evidence that hormone balance, genetics, and 
cholestasis may contribute to determine bone structure and density changes. There has been 
conflicting evidence as to whether PBC-related osteoporosis results from diminished bone 
formation, which is a low-turnover state, or from increased bone resorption, which is a high-
turnover state. However, recent data suggest that bone formation is the culprit. Cirrhosis is 
associated with the reduction of specific growth factors, such as insulin-like growth factor 1, which 
impairs osteoblast function and bone formation; severe cholestasis can allow build-up of lithocholic 
acid, which inhibits osteoblast activity and can interfere with genetic regulation of bone formation 
23. 
The prevalence of osteoporosis in cirrhotic patients ranges from 12 to 70% according to the 
diagnostic modality and the liver disease etiology, with cholestatic diseases having a higher 
prevalence (20-44%, even without an established diagnosis of cirrhosis). Moreover, fracture rates 
are increased in cholestatic diseases, varying from 13 to 22% according to the degree of liver 
function 120.  
Screening for osteoporosis is an important part of liver diseases management, and the guidelines 
indicate that patients with cirrhosis and PBC should be screened by an initial dual-energy X-ray 
absorptiometry (DXA) exam 121. If initial results are normal, the DXA should be repeated every 1 to 
3 years to assess significant bone loss, depending on the presence of additional risk factors (BMI 
less than 19 kg/m2, heavy alcohol use, tobacco use, early menopause [<age 45 years], 
glucocorticoid use greater than 3 months, or family history of bone fragility fractures). 121 In 
addition, BMD should be measured prior to liver transplantation.  
Laboratory test are also helpful for evaluating bone metabolism, and include serum calcium, 25-
hydroxyvitamin D, phosphorus, osteocalcin, procollagen I carboxyterminal peptide, and parathyroid 
hormone (PTH), as well as urinary amino telopeptides of collagen I and urinary calcium. Routine 
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monitoring of calcium, phosphorus, 25-hydroxyvitamin D, and PTH should be performed every 1 to 
2 years 123.  
The treatment of osteoporosis is based on results obtained from trials assessing postmenopausal 
women, and few studies have included patients with liver diseases. Educational strategies include 
elimination of modifiable risk factors, such as smoke and alcohol cessation. Calcium and vitamin D 
supplementation is part of osteoporosis treatment. The total calcium intake should achieve a daily 
ingestion of 1.0 to 1.5 grams, preferably from diet to facilitate patients compliance 120. Oral 
cholecaciferol (vitamin D3) can be prescribed at 1,000-4,000 IU per day or ergocalciferol (vitamin 
D2) at 50,000 IU per month. Given that  calcitriol (1,25-dihydroxycholecalciferol or 1,25-
dihydroxyvitamin D3) is the final active vitamin D metabolite, it may represent a better treatment 
for liver disease patients. Calcitriol is usually prescribed as a daily oral dose of 800 IU but can also 
be taken at a weekly dose of 5000 IU 120. In PBC, calcium and vitamin D supplementation alone 
was inferior to hormonal replacement therapy in improving BMD.124,125  However, testing for 
vitamin D deficiency in cholestatic patients is useful to allow for appropriate supplementation, 
particularly in those taking cholestyramine, since this impairs vitamin D absorption 116. 
Bisphosphonates represent the treatment of choice for osteoporosis in cirrhotic patients, because 
they attach to the bone surface and prevent resorption. 126. The threshold of intervention in patients 
with liver disease, however, may be lower than in the general population, since in PBC T-scores 
below -1.5 are associated with a significant risk for vertebral fractures 127. A recent randomized 
controlled trial for osteoporosis therapy in PBC patients showed that both monthly ibandronic acid 
and weekly alendronic acid improve bone mass and are comparable in safety, although adherence is 
higher with the monthly regimen 128. Moreover, bisphosphonates and teriparatide reduce the risk of 
vertebral fractures in chronically glucocorticoid-treated patients 129,130. Hormone replacement 
therapy does not show any osteoporosis benefit for PBC patients, but its use is no longer 
contraindicated in chronic cholestasis 131. Ultimately, treating PBC with UDCA may have 
beneficial effects also on the bone, since UDCA may increase osteoblast differentiation and 
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mineralization, and neutralize the detrimental effects of lithocholic acid, bilirubin and sera from 
jaundiced patients on osteoblastic cells 132.  
 
 
Concluding remarks. 
The coexistence of liver and rheumatic diseases represents an ideal example of the need for a 
interdisciplinary approach to individualize treatments. Indeed, patients with autoimmune liver 
diseases may be undertreated with anti-rheumatic drugs for liver safety concerns (as in the case of 
methotrexate), while liver test changes may raise unnecessary concerns. Furthermore, new biologics 
may be beneficial for more than one condition, though insufficient data exist from the hepatology 
perspective. Lastly, the rapid deterioration of bone health associated with chronic liver diseases is 
an obvious area of collaboration between gastroentology and rheumatology. With the current focus 
on personalized medicine, the coexistence of liver autoimmunity and rheumatic disease is an ideal 
area to develop and investigate the benefits of shared clinical practice. 
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Tables and figures. 
Table 1. Serum autoantibodies in autoimmune liver diseases.   
 
  
Antibody Liver disease  Prevalence 
ANA AIH  
PBC 
 
PSC 
Homogeneous pattern 34-58%, speckled 21-34% 
Nuclear pore complex targeting gp210 and nucleoporin p62, multiple 
nuclear dots targeting Sp100 – 50-70% 
20% 
SMA AIH  
PSC 
81% 
0-73% 
LKM 1 Type 2 AIH  
LC 1 Type 2 AIH 50%, only autoantibody in 10% of cases 
pANCA AIH  
PSC 
- 
33% 
SLA/LP AIH 10-30% 
LKM 3  Type 2 AIH  
ASGPR AIH 
PBC 
90% 
AMA AIH 
PBC 
9% 
90-95% 
ACA AIH 
PBC 
0-25% 
9-30% 
Anti-dsDNA AIH 
PBC 
23-34% 
0-22% 
Rheumatoid Factor AIH 21% 
Anti-Histones AIH 35% 
Anti-Ro/SSA AIH 
PBC 
26% 
10-28% 
Anti-La/SSB AIH 4.3% 
Anti-CCP AIH 9% 
Anti-cardiolipin 
IgG/IgM 
AIH 
PBC 
40% 
IgM 75% 
Anti-nucleosome AIH 
PBC 
PSC 
21.7% 
14.2% 
20% 
Anti-RNP AIH 
PSC 
8.6% 
5% 
Anti-Sm AIH 4.3% 
Anti-ribosomal P AIH 
PSC  
4.3% 
5% 
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Table 2. Revised Original Scoring System of the International Autoimmune Hepatitis Group 34. 
Criteria Points 
Sex 
Male 
Female 
 
0 
+2 
Ratio of ALP vs. AST/ALT 
>2.0 
1.5-2.0 
1.0-1.5 
<1.0 
 
+3 
+2 
+1 
0 
Autoantibodies (ANA, SMA, LKM1) titer 
>1:80 
1:80 
1:40 
<1:40 
 
+3 
+2 
+1 
0 
AMA 
Positive 
Negative 
 
-4 
0 
Seropositivity for other autoantibodies +2 
Viral hepatitis markers 
Negative 
Positive 
 
+3 
-3 
History of drug use 
Yes  
No 
 
-4 
+1 
Average alcohol consumption (g/day) 
<25 
>60 
 
+2 
-2 
Presence of genetic factors (HLA, DR3 or DR4) +1 
Presence of other autoimmune disorders (thyroiditis, colitis, others) +2 
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Liver histology 
Interface hepatitis 
Predominant lymphocytic infiltrate 
Rosetting of liver cells 
None of the above 
Biliary changes 
Other changes 
 
+3 
+1 
+1 
-5 
-3 
-3 
Response to therapy 
Complete 
Relapse 
 
+2 
+3 
 A score > 15 or > 17 indicates a definite diagnosis of AIH pre- or post-treatment, respectively. On 
the other hand, scores between 10–15 and 12–17 indicate a probable diagnosis, pre- or post-therapy, 
respectively. AMA, anti-mitochondrial autoantibodies; LKM-1, anti-liver–kidney microsomal 
antibodies; SMA, anti-smooth-muscle antibodies. 
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Table 3. Codified Diagnostic Criteria of the International Autoimmune Hepatitis Group 34. 
 
Features Definite Probable 
Liver histology Interface hepatitis of moderate or 
severe activity with or without 
lobular hepatitis or central portal 
bridging necrosis, but without biliary 
lesions or well defined granulomas 
or other prominent changes 
suggestive of a different etiology 
Same as for “definite” 
Serum biochemistry Any abnormality in serum 
aminotransferases, especially if the 
serum alkaline phosphatase is not 
markedly elevated. Normal serum 
concentrations of alpha antitrypsin, 
copper and ceruolasmin 
Same as for “definite” but patients 
with abnormal serum concentrations 
of copper or ceruloplasmin may be 
included, provided that Wilson 
disease has been excluded by 
appropriate investigations 
Serum immunoglobulins Total serum globulin or gamma 
globulin or IgG concentrations 
greater than 1.5 times the upper 
normal limit 
Any elevation of serum globulin or 
gamma globulin or IgG 
concentrations above the upper 
normal limit 
Serum autoantibodies Seropositivity for ANA, SMA or 
anti-LKM1 antibodies at titers 
greater than 1:80. Lower titers 
(particularly of anti-LKM1) may be 
significant in children. 
Seronegativity for AMA 
Same as for “definite” but at titers of 
1:40 or greater. Patients who are 
seronegative for these antibodies but 
who are seropositive for other 
antibodies may be included.  
Viral markers Seronegativity for markers of current 
infection with hepatitis A, B and C 
viruses 
Same as for “definite” 
Other etiological factors Average alcohol consumption less 
than 25g/day 
No history of recent use of known 
hepatotoxic drugs 
Alcohol consumption less than 
50g/day and no recent use of known 
hepatotoxic drugs 
Patients who have consumed larger 
amounts of alcohol or who have 
recently taken potentially 
hepatotoxic drugs may be included, 
if there is clear evidence of 
continuing liver damage after 
abstinence from alcohol or 
withdrawal of the drug 
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Table 4. Treatment of autoimmune liver diseases with rheumatic DMARDs and biologic therapy  
Drug Dosage Safety 
Autoimmune hepatitis   
Prednisone First-line treatment (1mg/kg/day, 
maximum 60 mg/day in 
monotherapy) 
Acute: hyperglycemia, high blood 
pressure 
Chronic: diabetes, osteoporosis, 
glaucoma, cataract 
Azathioprine 
 
Induction therapy (1-2mg/kg/day, 
maximum 200 mg/day) in 
combination with prednisone (30 
mg/day) 
Maintenance therapy (50 mg/day or 
up to 2 mg/kg/day) 
Leukopenia, liver toxicity, infections, 
nausea and vomiting 
Mycophenolate mofetil Second-line (1.5 to 2g daily) Infections, nausea and vomiting, 
cytopenia, contraindicated in pregnancy 
Cyclosporine Refractory cases (2-5 mg/kg daily) Hypertension, increased serum 
creatinine, hirsutism 
Methotrexate Refractory cases: Case reports Liver toxicity, infections, 
contraindicated in pregnancy 
Infliximab Refractory cases: Case reports Liver toxicity, induction of AIH, 
contraindicated in pregnancy 
Rituximab Refractory cases: Case reports contraindicated in pregnancy 
Primary biliary cholangitis   
Azathioprine 
 
Refractory cases (50 mg/day) + 
prednisone (30mg/day) + UDCA 
Leukopenia, liver toxicity, infections, 
nausea and vomiting 
Cyclosporine Refractory cases  Hypertension, increased serum 
creatinine, hirsutism 
Methotrexate Refractory cases (0.25 mg/kg/week 
per os) 
Liver toxicity, infections, 
contraindicated in pregnancy 
Mycophenolate mofetil Refractory cases (1-2 mg/day) Infections, nausea and vomiting, 
cytopenia, contraindicated in pregnancy 
Colchicine Refractory cases (1.2mg/day) 
 
Diarrhea, myelosuppression 
Ustekinumab Under evaluation (90 mg sc weeks 0 
-4 and then every 8 weeks) 
Infections, contraindicated in pregnancy 
Abatacept Under evaluation - 
Primary sclerosing cholangitis   
Cyclosporine Refractory cases  Hypertension, increased serum 
creatinine, hirsutism 
Methotrexate Refractory cases Liver toxicity, infections, 
contraindicated in pregnancy 
UDCA: ursodeoxycholic acid 
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Table 5. Diagnostic criteria for Primary Biliary Cholangitis (PBC). Diagnosis is made in the 
presence of at least 2 out of 3 of the criteria.  
 
Parameters 
Elevated ALP > 2 x ULN or GGT > 5 x ULN 
AMA positivity 
Chronic granulomatous cholangitis at liver biopsy 
ALP: alkaline  phosphatase; ULN: upper limit of normal; GGT: γ-glutamyltransferase; AMA: 
antimitochondrial antibodies.   
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Table 6. Diagnostic features of overlap syndromes. 
Overlap Syndrome Laboratory features Histologic findings 
AIH/PBC ANA or SMA 
Hypergammaglobulinemia 
Serum IgG increased 
Marked serum AST/ALT abnormalities  
AP or GGT > ULN 
AMA positive 
Interface hepatitis 
Lymphocytic portal infiltrate 
Portal plasma cells 
Destructive cholangitis 
AIH/PBC 
(Paris criteria) 
AIH features (2 of 3): 
Serum ALT5-fold ULN 
Serum IgG2-fold ULN or 
SMA present 
Interface hepatitis 
PBC features (2 of 3): 
Serum AP2-fold ULN or GGT 
5-fold ULN 
AMA positive 
Florid duct lesions 
Interface hepatitis (moderate 
to severe) 
Destructive cholangitis 
AIH/PSC ANA or SMA 
Hypergammaglobulinemia 
Serum IgG increased 
Marked serum AST/ALT abnormalities  
Focal biliary strictures and dilations 
Lymphocytic portal infiltrate 
Ductular proliferation 
Periductular fibrosis 
Portal edema 
Cholate stasis 
Fibrous obliterative 
cholangitis (rare) 
Ductopenia 
Increased stainable hepatic 
copper 
AIH and undefined 
cholestatic 
syndrome 
ANA or SMA 
Hypergammaglobulinemia 
Serum IgG increased 
Marked serum AST/ALT abnormalities  
AMA negative 
No biliary strictures and dilations 
Interface hepatitis plus at 
least: 
Destructive cholangitis 
Periductular fibrosis 
Ductopenia 
Portal edema 
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